ST红太阳(000525) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥747,388,776.20, a decrease of 51.10% compared to ¥1,528,497,781.36 in the same period last year[3] - The net profit attributable to shareholders was ¥11,316,969.11, down 96.30% from ¥305,590,608.32 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥14,537,586.97, a decline of 95.38% compared to ¥314,700,365.59 in the previous year[3] - The net cash flow from operating activities was ¥67,421,620.44, representing a 53.01% decrease from ¥143,475,487.35 in the same period last year[3] - Total revenue for Q1 2023 was ¥747,388,776.20, a decrease of 51.1% compared to ¥1,528,497,781.36 in the same period last year[16] - Net profit for Q1 2023 was ¥7,697,450.67, compared to a net profit of ¥302,575,278.68 in Q1 2022, indicating a significant decline[16] - The net profit attributable to the parent company for Q1 2023 is ¥11,316,969.11, a decrease from ¥305,590,608.32 in the previous period[17] - The total comprehensive income attributable to the parent company is ¥11,316,969.11, compared to ¥305,590,608.32 in the previous period[17] - Basic and diluted earnings per share for Q1 2023 are both ¥0.0195, down from ¥0.5262 in the previous period[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,054,719,865.46, a decrease of 2.20% from ¥10,280,802,563.89 at the end of the previous year[3] - Total liabilities decreased to ¥8,633,361,219.71 from ¥8,882,507,428.55, reflecting a decline of 2.8%[14] - Current assets totaled ¥4,986,155,727.65, down 4.1% from ¥5,198,301,733.47 at the beginning of the year[14] - The company's total assets decreased to ¥10,054,719,865.46 from ¥10,280,802,563.89 at the beginning of the year, a reduction of 2.2%[14] - The company's equity attributable to shareholders increased to ¥1,287,580,388.51 from ¥1,271,285,338.83, a rise of 1.3%[14] Cash Flow - Cash inflow from operating activities for Q1 2023 is ¥734,286,535.82, a decrease from ¥1,581,523,644.29 in the previous period[18] - Cash outflow from investing activities is ¥46,071,836.62, compared to ¥29,156,992.09 in the previous period[19] - Net cash flow from financing activities is -¥91,247,603.18, an improvement from -¥100,805,780.36 in the previous period[19] - The ending cash and cash equivalents balance is ¥144,913,759.77, compared to ¥95,369,688.72 in the previous period[19] - The company received cash from sales of goods and services amounting to ¥558,357,780.45, down from ¥1,198,071,772.59 in the previous period[18] - The company paid cash to employees totaling ¥115,159,824.67, a decrease from ¥167,471,037.64 in the previous period[19] Expenses and Costs - Total operating costs for Q1 2023 were ¥754,331,508.01, down 37.0% from ¥1,194,201,409.70 year-over-year[16] - Research and development expenses for Q1 2023 were ¥45,162,420.36, down 22.7% from ¥58,433,681.04 in the previous year[16] - The company experienced a 72.14% reduction in selling expenses, which amounted to ¥10,348,110.37 compared to ¥37,149,599.69 in the same period last year[6] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,518[7] - The largest shareholder, Nanjing First Pesticide Group Co., Ltd., holds 31.50% of shares, totaling 182,924,731 shares[7] Corporate Actions and Investigations - Nanjing Hongtaiyun Business Co., Ltd. transferred its 51% stake in Anhui Hongtai Biological Chemical Co., Ltd. to Nanjing Huazhou Pharmaceutical Co., Ltd.[10] - The registered capital of Nanjing Xinzou Technology Co., Ltd. was set at 20 million RMB, with Nanjing Huazhou Pharmaceutical holding 49%[10] - The company’s shareholding in Zhongnong Hongtai (Nanjing) Biotechnology Co., Ltd. decreased from 42% to 10%[10] - The company is under investigation by the China Securities Regulatory Commission for information disclosure violations[9] - The company’s stock continues to be subject to "other risk warnings" as per the Shenzhen Stock Exchange regulations[9] - The company reported a significant amount of pledged and frozen shares among its major shareholders[8] Credit and Impairment - The company reported a significant increase in credit impairment losses, which rose by 284.12% to ¥17,985,354.58 compared to a loss of ¥9,768,175.31 in the previous year[6]